Institute of Medicine Releases Report on Studying the Safety of Approved Drugs - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Institute of Medicine Releases Report on Studying the Safety of Approved Drugs


ePT--the Electronic Newsletter of Pharmaceutical Technology

At the request of FDA, the Institute of Medicine (IOM) prepared a report containing recommendations for how the agency might better monitor the safety of drugs after they have been approved. The report, titled Ethical and Scientific Issues in Studying the Safety of Approved Drugs, recommends a life-cycle approach to safety monitoring. In such an approach, processes are in place to collect, assess, and act on data about a medication's benefit-risk profile from approval until it is no longer marketed.

One of the report’s key recommendations is that FDA should create a benefit and risk assessment and management plan for each drug in the form of a single, comprehensive, publicly available document. This document would serve as a central repository of information for each product from its approval throughout its entire time on the market. The report also recommended enhanced surveillance for certain categories of higher-risk drugs, such as first-in-class molecules, drugs approved through the use of several surrogate endpoints that provide conflicting evidence about likely health outcomes associated with the drug, or drugs that have a strong biological rationale for a particular side effect.

"We believe that the adoption of a life-cycle approach to drug approval and monitoring will help the agency strengthen its oversight, better tackle these complex decisions, and increase public confidence in the agency's ability to protect public health," said Steven N. Goodman, professor of medicine, health research, and policy, and associate dean for clinical and translational research at Stanford University School of Medicine, in an accompanying press release. "This will become increasingly important as FDA looks for ways to safely expedite the drug approval process."

FDA notes that many of the recommendations in the report are in step with ongoing agency programs and processes. In a statement issued by the Center for Drug Evaluation and Research the agency notes, “FDA monitors a drug’s safety throughout its lifecycle, and considers the oversight of drugs once they reach the market of equal importance to the premarket review of new drug and biologics applications.” FDA also says that while the creation of a central, publicly-accessible risk management plan for each drug is a good recommendation, they are too resource constrained at this time to implement such a program. The agency says it is in the process of fully analyzing the report to determine how to implement changes that will have the largest positive impact on public health.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
27%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
32%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here